Junya Ako
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (11)
Background Combination therapy with atherectomy and intravascular lithotripsy (IVL) has emerged as a promising strategy for the treatment of severely calcified occlusive coronary lesions, which potentially enhances procedural efficacy without increasing complication risk. Methods The Dual-Prep Registry is a multicenter, prospective registry designed to evaluate the safety and efficacy of IVL after atherectomy in severely calcified lesions. Combined use was selectively applied when the risk of complications was anticipated to be high with a larger atherectomy burr size, or when it was deemed non-beneficial due to unfavorable guidewire bias. All adverse events were adjudicated by a clinical events committee. Kaplan-Meier analysis was performed to evaluate the primary endpoint of major adverse cardiovascular events (MACE; composite endpoint of cardiac death, myocardial infarction, and target vessel revascularization [TVR]) at 1 year. Results A total of 118 cases (120 lesions) were enrolled across 20 facilities. Significant comorbidities included diabetes in 56.8% of patients and hemodialysis-dependence in 25.4%. Calcification score after atherectomy was 4.0 in all cases, and calcified nodules were present in 56.4% (core-lab analysis) of cases. One-year follow-up was complete in 99.2% patients. MACE occurred in 7.6% patients at one year (cardiac death 2.5%, myocardial infarction 5.1%, TVR 5.1%) and stent thrombosis was observed in 1 case. Conclusions Atherectomy followed by IVL resulted in low 1-year rates of MACE, TVR, and stent thrombosis in patients with severely calcified coronary lesions. This approach may be considered for lesions where an “IVL-first” strategy is difficult to apply. Japan Registry of Clinical Trials: jRCT1032230384. URL: https://jrct.mhlw.go.jp A Clinical Perspective 1) What Is New? Elective combined use of IVL and atherectomy resulted in low 1 year MACE and TLR. The incidence of MACE was higher in cases with greater residual stenosis after the procedure and a larger baseline reference vessel diameter. 2) What Are the Clinical Implications? Combining IVL with atherectomy may serve as an effective treatment strategy in cases where IVL-first approaches are difficult to apply. Severe calcified lesions that are presumed to be unresponsive to RA/OA treatment or carry a high risk of RA/OA complications may be good candidates for this strategy.
Year:
2025
Background Standardized protocols with optimal hemodynamic targets for percutaneous ventricular assist device (PVAD) management remain undefined. We aimed to evaluate the proportion of phase‐specific hemodynamic criteria achieved during PVAD support and their association with outcomes in patients with cardiogenic shock. Methods This multicenter retrospective study enrolled patients with cardiogenic shock requiring PVAD (Impella). Patients were evaluated at 24 hours post‐PVAD, venoarterial extracorporeal membrane oxygenation weaning, and PVAD weaning. Hemodynamic criteria consisted of key targets, including mean arterial pressure ≥60 mm Hg, lactate <2.0 mmol/L, right atrial pressure <15 mm Hg, pulmonary artery wedge pressure <20 mm Hg, pulmonary artery pulsatility index ≥1.0, and cardiac power output ≥0.6 W. The primary outcome was a composite of 30‐day all‐cause mortality and unplanned mechanical circulatory support reintroduction. Results A total of 501 patients were enrolled: 206 (41%) with PVAD alone and 295 (59%) with PVAD and venoarterial extracorporeal membrane oxygenation. The majority of patients were supported with Impella CP (406, 81%). Fulfillment of criteria was observed in 37%, 52%, and 45% at 24 hours post‐PVAD, venoarterial extracorporeal membrane oxygenation weaning, and PVAD weaning, respectively. Patients with unfulfilled criteria at each evaluation point were at high risk for the primary outcome (hazard ratio, 3.2 [95% CI, 2.1–4.8]; hazard ratio, 2.1 [1.2–3.7]; and hazard ratio, 2.0 [95% CI, 1.1–3.6]). Hemodynamic criteria achievement consistently stratified the risk of the primary outcome across different subgroups, including shock cause, shock stage, and concomitant use of venoarterial extracorporeal membrane oxygenation. Conclusions Phase‐specific hemodynamic criteria are often unmet and are associated with significantly higher risks of short‐term fatal events.
Year:
2025
Backgrounds Atrial fibrillation (AF) is a risk factor for adverse cardiovascular outcomes in patients with stable coronary artery disease (CAD). The prognostic relevance of lower systolic blood pressure (SBP) and the optimal antithrombotic strategy in patients with AF and CAD remain to be clarified. Methods This post-hoc analysis of the AFIRE (Atrial Fibrillation and Ischemic Events with Rivaroxaban in Patients with Stable Coronary Artery Disease) trial stratified participants based on median SBP at baseline: >126 mmHg (High SBP group, n=1042) and ≤126 mmHg (Low SBP group, n=1093). The primary efficacy endpoint was a composite of cardiovascular events and all-cause death. The primary safety endpoint was major bleeding. Results The mean SBP was 139 mmHg and 114 mmHg in the High and Low SBP groups, respectively. In the propensity score-matched cohort (n=1684), the Low SBP group had a significantly higher incidence of the primary efficacy endpoint (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.01–1.88; p=0.039), while the primary safety endpoint was comparable between groups. In the Low SBP group, rivaroxaban monotherapy was associated with lower risks of both the primary efficacy (HR, 0.66; 95% CI, 0.41–0.86; p=0.006) and safety endpoints (HR, 0.40; 95% CI, 0.22–0.74; p=0.003) compared with combination therapy, whereas no significant differences were observed in the High SBP group. Conclusions Lower SBP was associated with increased risk of cardiovascular events and all-cause death. Rivaroxaban monotherapy demonstrated more favorable efficacy and safety outcomes compared with combination therapy, particularly among patients with lower SBP.
Year:
2025
Background Catheter ablation (CA) can improve exercise tolerance and quality of life (QOL) in patients with atrial fibrillation (AF). However, its differential effects on muscle strength between paroxysmal AF (PAF) and nonparoxysmal AF (Non‐PAF) remain unclear. Methods We evaluated 94 patients (67.8 ± 10.3 years old, 71% male) who underwent CA (PAF/Non‐PAF 46/48) without AF recurrence. Six‐minute walk distance (6MWD), leg strength, and an AF‐specific QOL questionnaire (AFQLQ) were evaluated at baseline, 3, and 6 months after CA. Results At baseline, the 6MWD and AFQLQ subset 3 score were significantly lower in patients with PAF than in those with Non‐PAF, but the parameters of muscle strength were comparable between the two groups. Both 6MWD and AFQLQ significantly improved at 6 months after CA in both groups. However, leg strength at 6 months after CA significantly improved in the Non‐PAF group (54.9 ± 16.5 to 58.4 ± 15.2, p < .05) but not in the PAF group. Conclusion Successful CA for both PAF and Non‐PAF improved QOL and exercise tolerance. Additionally, CA improved leg strength in Non‐PAF patients.
Year:
2025
Introduction: Small airway is reportedly more susceptible than central airways in heart failure (HF), which may cause poor outcomes. We investigated clinical significance of small-airway disease (SAD) on exercise intolerance and clinical events in patients with HF and reduced or preserved left ventricular ejection fraction (LVEF). Methods: We studied consecutive patients with HF admitted for medical treatment and measured maximum mid-expiratory flow (MMEF) on spirometry and 6-min walking distance (6MWD) at hospital discharge. SAD and exercise intolerance were defined by MMEF relative to <60% of the predicted value and 6MWD <300 m, respectively. Endpoint was composite clinical events of all-cause death and/or HF readmission. Results: Among 1,016 studied patients, 478 (47.0%) had SAD, the prevalence of which was higher in patients with LVEF ≥40% than LVEF <40%. SAD correlated to 6MWD <300 m (adjusted odds ratio [aOR]: 4.23, 95% confidence interval [CI]: 2.49–7.19). This correlation was consistently observed in both LVEF <40% (aOR: 3.99, 95% CI: 1.59–9.98) and LVEF ≥40% (aOR: 4.50, 95% CI: 2.22–9.13). SAD also showed significant associations with high incidences of clinical events in all patients (adjusted hazard ratio [aHR]: 1.35, 95% CI: 1.05–1.72) and in LVEF <40% (aHR: 1.76, 95% CI: 1.21–2.54) but not in LVEF ≥40% (aHR: 1.10, 95% CI: 0.78–1.53). Conclusion: The prevalence of SAD is high in patients with HF, which is associated with exercise intolerance regardless of LVEF. Additionally, SAD may have a predictive significance for clinical events in these patients, especially in LVEF <40%.
Year:
2024
Introduction: The vascular endothelial glycocalyx, crucial for blood vessel integrity and homeostasis, is vulnerable to oxidative stress, leading to endothelial dysfunction, which strongly correlates with cardiovascular disease (CVD). This study investigates the protective effects of rivaroxaban, a factor X inhibitor, on the glycocalyx under oxidative stress condition. Methods: We examined the impact of rivaroxaban on human umbilical vein endothelial cells exposed to acute and chronic H 2 O 2 -induced oxidative stress. Results: Rivaroxaban dose-dependently suppressed syndecan-1, a key component of the glycocalyx, shedding from cell surface, and enhanced protease-activated receptor (PAR)1-PAR2/phosphatidylinositol-3-kinase (PI3K)-dependent cell viability after acute induction of H 2 O 2 . This protective effect was linked to the translocation of IQGAP1, a scaffold protein that modulates the actin cytoskeleton, to the perinucleus from the cell membrane. Under chronic H 2 O 2 treatments, rivaroxaban improves cell viability accompanied by an increase in hyaluronidase activities, aiding the turnover and remodeling of hyaluronic acid within the glycocalyx. Conclusion: We identify that rivaroxaban protects against oxidative stress-induced endothelial glycocalyx damage and cell viability through IQGAP1/PAR1-2/PI3K/Akt pathway, offering a potential to be a therapeutic target for CVD prevention.
Year:
2024
Background Evolocumab is the first monoclonal antibody against proprotein convertase subtilisin/kexin type 9 approved in Japan for familial hypercholesterolemia (FH) and hypercholesterolemia; however, data on its safety and effectiveness in the real‐world setting in Japan are limited. Methods and Results This real‐world, postmarketing, single‐arm study assessed the safety and effectiveness of low‐density lipoprotein cholesterol lowering with evolocumab in patients with homozygous/heterozygous familial hypercholesterolemia and hypercholesterolemia with high risk in Japan (668 sites). The primary safety end point was the incidence (percentage) and number of patients with adverse drug reactions and serious adverse events during the 104‐week follow‐up. Primary effectiveness end points included the percentage change in low‐density lipoprotein cholesterol levels from baseline to week 12, assessed using 2‐sided paired t tests. The safety and effectiveness sets comprised 3724 (homozygous FH, n=108; heterozygous FH, n=2009; hypercholesterolemia with high risk, n=1607) and 2797 (homozygous FH, n=91; heterozygous FH, n=1615; hypercholesterolemia with high risk, n=1091) patients, respectively. Overall, mean age and disease duration were 63.2 and 12.3 years, respectively. Serious adverse drug reactions and serious adverse events were experienced by 0.5% and 10.3% of patients; the incidence rates of myocardial infarction and stroke were 0.7% and 0.3%, respectively. A significant mean±SD percentage change in low‐density lipoprotein cholesterol levels was observed at week 12 among patients with homozygous FH (−45.7%±28.2; P <0.001), heterozygous FH (−55.9%±28.8; P <0.001), and hypercholesterolemia with high risk (−63.3%±23.7; P <0.001). Conclusions Evolocumab was well tolerated, and real‐world patients with familial hypercholesterolemia and hypercholesterolemia with high risk in Japan had sustained low‐density lipoprotein cholesterol reduction. REGISTRATION URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT02808403.
Year:
2024
Stenosis of the left main coronary artery (LM stenosis) is associated with significant mortality and morbidity due to the large area of affected myocardium. Evidence on the use of percutaneous coronary intervention (PCI) for the treatment of LM stenosis is growing. However, the role of Western guidelines on patients in the Asian-Pacific region is unclear due to anatomical variations, substantial heterogeneity in healthcare resources and infrastructure, and the lack of consensus on the optimal management of LM stenosis in the Asia-Pacific region. Hence, an Asian Pacific Society of Cardiology (APSC) working group developed consensus recommendations on the use of PCI in the management of LM stenosis in the Asia-Pacific region. The APSC expert panel reviewed and appraised the available evidence using the Grading of Recommendations Assessment, Development, and Evaluation system. Consensus recommendations were developed and put to an online vote. Consensus was reached when 80% of votes for a given recommendation were in support of ‘agree’ or ‘neutral’. The resulting 12 statements provide guidance for clinical practitioners in the region on the use of PCI in the treatment of patients with LM stenosis.
Year:
2024
Background Right ventricular volume overload is the key finding in a patient with previously undiagnosed atrial septal defect (ASD). Case summary A 68-year-old female was referred to our hospital due to progressive pulmonary artery dilatation observed on her chest X-ray. Echocardiography revealed a secundum ASD with right ventricular dilatation. She had undergone aortic root replacement and aortic valve replacement for annuloaortic ectasia and aortic insufficiency 12 years prior to the diagnosis. She was also diagnosed with Marfan syndrome, which was supported by family histories. Computed tomography did not show a secundum ASD before the surgery. We finally closed the secundum ASD with catheter closure device. Discussion Ascending aneurysm might mask the presence of secundum ASD. Monitoring the change in pulmonary artery dilatation overtime is useful for the diagnosing secundum ASD.
Year:
2024
BACKGROUND: It is not known whether there is a sex difference in the association between perivascular inflammation and plaque vulnerability. The aim of this study was to investigate the sex-specific association between perivascular inflammation and plaque vulnerability. METHODS: Patients who underwent coronary computed tomography angiography and optical coherence tomography were enrolled. All images were analyzed at a core laboratory. The level of perivascular inflammation was assessed by pericoronary adipose tissue attenuation on computed tomography angiography and the level of plaque vulnerability by optical coherence tomography. Patients were classified into 3 groups according to tertile levels of culprit vessel pericoronary adipose tissue attenuation (low inflammation, ≤−73.1 Hounsfield units; moderate inflammation, −73.0 to −67.0 Hounsfield units; or high inflammation, ≥−66.9 Hounsfield units). RESULTS: A total of 968 lesions in 409 patients were included: 184 lesions in 82 women (2.2 plaques per patient) and 784 lesions in 327 men (2.4 plaques per patient). Women were older (median age, 71 versus 65 years; P <0.001) and had less severe coronary artery disease with a lower plaque burden than men. In women, it was found that perivascular inflammation was significantly associated with plaque vulnerability, with a higher prevalence of thin-cap fibroatheroma and greater macrophage grades in the high inflammation group compared with the low inflammation group (low versus moderate versus high inflammation in women: 18.5% versus 31.8% versus 46.9%, P =0.002 for low versus high inflammation; 3 versus 4 versus 12, P <0.001 for low versus high inflammation, respectively). However, no significant differences were observed among the 3 groups in men. CONCLUSIONS: Perivascular inflammation was associated with a higher prevalence of thin-cap fibroatheroma and more significant macrophage accumulation in women but not in men. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04523194.
Year:
2024
Year:
2023
Collaborators (9)
Hidehira Fukaya
Junior Associate Professor
Kitasato University School of Medicine
Tsunekazu Kakuta
-
Koutaro Yokote
Chiba University Graduate School of Medicine
Shinichi Niwano
Clinical Professor
Kitasato University
Masato Nakamura
Professor
Toho University
Tetsuya Matoba
Associate Professor
Kyushu University Hospital
Gaku Nakazawa
Kindai University Hospital
Ken Kozuma
-
Kazuo Kitagawa
Professor and Chairman
Tokyo Women's Medical University
Make your next move.
Prepare your application
Review drafts before you send them.